PMV Pharmaceuticals, Inc. (PMVP)
Nasdaq · Healthcare · Biotechnology
$1.78−0.56%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $134M
- 52-week range
- $1.02 – $1.91
- 52-week change
- +31.62%
- EPS (trailing)
- −$1.42
- Next earnings
- Nov 16, 2026
Fiscal year to Dec 2025
- Net income
- −$77.7M
- Diluted EPS
- −$1.48
- Free cash flow
- −$73.6M
From the company’s annual report on SEC EDGAR.
About PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.
Headquarters: Princeton, United States · 54 employees · pmvpharma.com